Enveric Biosciences (ENVB) EBT Margin (2014 - 2020)
Enveric Biosciences (ENVB) posted EBT Margin of 11.66% for Q3 2020, up 38.14% sequentially from 18.85% in Q2 2020, and down 1210.0% YoY from 1.05% in Q4 2019.
Enveric Biosciences (ENVB) EBT Margin (2014 - 2020) Analysis & Trends
Enveric Biosciences has reported EBT Margin for 7 years, with the latest figure at 11.66% in Q3 2020.
- Quarterly EBT Margin fell 1210.0% year-over-year to 11.66% in Q3 2020, while the trailing twelve-month figure through Sep 2020 was 18.18% (up 2201.0% YoY) and the FY2019 annual result came in at 13.08%, up 1146.0% from the prior year.
- EBT Margin climbed to 11.66% in Q3 2020 per ENVB's latest filing, from 18.85% in the prior quarter.
- Over five years, EBT Margin peaked at 54.13% in Q3 2018 and troughed at 130.71% in Q4 2018.
- A 5-year average of 19.41% and a median of 17.7% in 2019 frame the typical range for EBT Margin.
- The sharpest annual moves came in 2018 and 2019: EBT Margin plunged 10089 bps in 2018, then surged 10723 bps in 2019.
- Over 5 years, EBT Margin stood at 19.72% in 2016, then sank by 51 bps to 29.82% in 2017, then sank by 338 bps to 130.71% in 2018, then soared by 82 bps to 23.48% in 2019, then jumped by 50 bps to 11.66% in 2020.
- According to Business Quant data, EBT Margin over the past three periods registered 11.66%, 18.85%, and 18.36% for Q3 2020, Q2 2020, and Q1 2020 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 35.71% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -528.97% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 18.33% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 13.77% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -25.06% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -2.67% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 12.09% |
| 10 | Enveric Biosciences | 5.66 Mn | -2.64 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | -11.66% |
| Jun 30, 2020 | -18.85% |
| Mar 31, 2020 | -18.36% |
| Dec 31, 2019 | -23.48% |
| Sep 30, 2019 | 0.44% |
| Jun 30, 2019 | -11.26% |
| Mar 31, 2019 | -17.70% |
| Dec 31, 2018 | -130.71% |
| Sep 30, 2018 | 54.13% |
| Jun 30, 2018 | -11.38% |
| Mar 31, 2018 | -14.21% |
| Dec 31, 2017 | -29.82% |
| Sep 30, 2017 | -32.41% |
| Jun 30, 2017 | -26.61% |
| Mar 31, 2017 | -5.88% |
| Dec 31, 2016 | -19.72% |
| Sep 30, 2016 | -17.67% |
| Jun 30, 2016 | -18.08% |
| Mar 31, 2016 | -15.62% |
| Dec 31, 2015 | -23.68% |